Author: Pinato, David J.; Lee, Alvin J. X.; Biello, Federica; SeguÃ, Elia; Aguilar-Company, Juan; Carbó, Anna; Bruna, Riccardo; Bower, Mark; Rizzo, Gianpiero; Benafif, Sarah; Carmona, Carme; Chopra, Neha; Cruz, Claudia Andrea; D’Avanzo, Francesca; Evans, Joanne S.; Galazi, Myria; Garcia-Fructuoso, Isabel; Dalla Pria, Alessia; Newsom-Davis, Thomas; Ottaviani, Diego; Patriarca, Andrea; Reyes, Roxana; Sharkey, Rachel; Sng, Christopher C. T.; Wong, Yien Ning Sophia; Ferrante, Daniela; Scotti, Lorenza; Avanzi, Gian Carlo; Bellan, Mattia; Castello, Luigi Mario; Marco-Hernández, Javier; Mollà , Meritxell; Pirisi, Mario; Ruiz-Camps, Isabel; Sainaghi, Pier Paolo; Gaidano, Gianluca; Brunet, Joan; Tabernero, Josep; Prat, Aleix; Gennari, Alessandra
Title: Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe Cord-id: 0wo2ak08 Document date: 2020_7_8
ID: 0wo2ak08
Snippet: We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged >18 (mean = 69) and diagnosed with COVID-19 between 26 February and 1 April 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had >1 co-morb
Document: We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged >18 (mean = 69) and diagnosed with COVID-19 between 26 February and 1 April 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had >1 co-morbidity. A total of 141 (69%) patients had >1 COVID-19 complication. A total of 36 (19%) were escalated to high-dependency or intensive care. A total of 59 (29%) died, 53 (26%) were discharged, and 92 (45%) were in-hospital survivors. Mortality was higher in patients aged >65 (36% vs. 16%), in those with >2 co-morbidities (40% vs. 18%) and developing >1 complication from COVID-19 (38% vs. 4%, p = 0.004). Multi-variable analyses confirmed age > 65 and >2 co-morbidities to predict for patient mortality independent of tumor stage, active malignancy, or anticancer therapy. During the early outbreak of SARS-CoV-2 infection in Europe co-morbid burden and advancing age predicted for adverse disease course in cancer patients. The ongoing OnCovid study will allow us to compare risks and outcomes in cancer patients between the initial and later stages of the COVID-19 pandemic.
Search related documents:
Co phrase search for related documents- academic center and acute illness: 1, 2, 3, 4, 5, 6, 7, 8, 9
- academic center and acute oncology: 1, 2
- academic center and acute pressure: 1, 2
- academic center and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- academic center and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- academic center and acute respiratory failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- academic center and acute service: 1, 2, 3, 4
- academic center and acutely ill: 1
- active anticancer and acute respiratory: 1, 2, 3, 4, 5, 6
- active anticancer therapy and acute respiratory: 1, 2
- active malignancy and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- active malignancy and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7
- active malignancy and acute respiratory failure: 1, 2, 3, 4
- active malignancy evidence and acute respiratory: 1
- active malignancy evidence and acute respiratory failure: 1
Co phrase search for related documents, hyperlinks ordered by date